X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (19) 19
imatinib (17) 17
chronic myeloid leukemia (16) 16
dasatinib (16) 16
humans (15) 15
nilotinib (14) 14
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (12) 12
oncology (12) 12
hematology (11) 11
aged (10) 10
chronic myelogenous leukemia (10) 10
female (10) 10
male (10) 10
3-year follow-up (9) 9
leukemia (9) 9
middle aged (9) 9
tyrosine kinase inhibitors (9) 9
adult (8) 8
follow-up (8) 8
hemic and lymphatic diseases (8) 8
phase-3 trial dasision (8) 8
tyrosine (8) 8
aged, 80 and over (7) 7
cancer (7) 7
dasision (7) 7
patients (7) 7
trial dasision (7) 7
molecular response (6) 6
myeloid leukemia (6) 6
protein kinase inhibitors - therapeutic use (6) 6
protein-tyrosine kinase (6) 6
antineoplastic agents - therapeutic use (5) 5
leukemia, myelogenous, chronic, bcr-abl positive - mortality (5) 5
protein kinase inhibitors - administration & dosage (5) 5
pyrimidines - administration & dosage (5) 5
survival (5) 5
tyrosine kinase inhibitor (5) 5
antineoplastic agents - administration & dosage (4) 4
antineoplastic agents - adverse effects (4) 4
clinical trials (4) 4
dasatinib - administration & dosage (4) 4
diagnosed chronic-phase (4) 4
drug resistance, neoplasm (4) 4
early molecular response (4) 4
efficacy (4) 4
imatinib mesylate - adverse effects (4) 4
management (4) 4
phenols (4) 4
pyrimidines - adverse effects (4) 4
pyrimidines - therapeutic use (4) 4
recommendations (4) 4
young adult (4) 4
2-year follow-up (3) 3
abridged index medicus (3) 3
adolescent (3) 3
adverse events (3) 3
analysis (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
article (3) 3
bcr-abl (3) 3
bcr-abl1 (3) 3
care and treatment (3) 3
cml (3) 3
comorbidity (3) 3
dasatinib - adverse effects (3) 3
follow-up studies (3) 3
imatinib mesylate (3) 3
imatinib mesylate - administration & dosage (3) 3
imatinib-resistant (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - epidemiology (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - genetics (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - pathology (3) 3
medicine & public health (3) 3
molecular targeted therapy (3) 3
oncology, experimental (3) 3
original (3) 3
outcomes (3) 3
protein kinase inhibitors - adverse effects (3) 3
research (3) 3
safety (3) 3
survival rate (3) 3
therapy (3) 3
thiazoles - therapeutic use (3) 3
400 mg (2) 2
adherence (2) 2
antineoplastic agents - economics (2) 2
benzamides - therapeutic use (2) 2
cells (2) 2
chromosome-positive leukemias (2) 2
chronic myeloid-leukemia (2) 2
clinical-trials (2) 2
cohort studies (2) 2
complete cytogenetic response (2) 2
complications and side effects (2) 2
dasatinib - blood (2) 2
dasision trial (2) 2
disease-free survival (2) 2
expansion (2) 2
fusion proteins, bcr-abl - antagonists & inhibitors (2) 2
fusion proteins, bcr-abl - biosynthesis (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 13, pp. 1330 - 1338
PurposeSafe, effective treatments are needed for pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP). Dasatinib is approved for... 
CHRONIC MYELOGENOUS LEUKEMIA | IMATINIB-RESISTANT | INTOLERANT | MANAGEMENT | ONCOLOGY | ADOLESCENTS | FOLLOW-UP | DOSE IMATINIB | DASISION | CANCER | CHILDREN | ORIGINAL REPORTS
Journal Article
Blood, ISSN 0006-4971, 07/2015, Volume 126, Issue 1, pp. 42 - 49
Journal Article
Journal Article
Journal Article
Journal Article
American Journal of Hematology, ISSN 0361-8609, 04/2015, Volume 90, Issue 4, pp. 282 - 287
Journal Article
Hematology, ISSN 1520-4391, 2016, Volume 2016, Issue 1, pp. 164 - 169
Multiple tyrosine kinase inhibitors (TKIs) are available for managing patients with chronic myeloid leukemia. Although most patients have a favorable outcome... 
TYROSINE KINASE INHIBITORS | CHRONIC MYELOGENOUS LEUKEMIA | 400 MG | DIAGNOSED CHRONIC-PHASE | TRIAL DASISION | IMATINIB | CYTOGENETIC RESPONSE | FOLLOW-UP | HEMATOLOGY | EDUCATION, SCIENTIFIC DISCIPLINES | NILOTINIB | CROSS-INTOLERANCE
Journal Article